| High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden R Benayed, M Offin, K Mullaney, P Sukhadia, K Rios, P Desmeules, ... Clinical Cancer Research 25 (15), 4712-4722, 2019 | 395 | 2019 |
| SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization MK Baine, MS Hsieh, WV Lai, JV Egger, AA Jungbluth, Y Daneshbod, ... Journal of Thoracic Oncology 15 (12), 1823-1835, 2020 | 373 | 2020 |
| Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer AJ Schoenfeld, JM Chan, D Kubota, H Sato, H Rizvi, Y Daneshbod, ... Clinical Cancer Research 26 (11), 2654-2663, 2020 | 321 | 2020 |
| MET-dependent solid tumours—molecular diagnosis and targeted therapy R Guo, J Luo, J Chang, N Rekhtman, M Arcila, A Drilon Nature Reviews Clinical Oncology 17 (9), 569-587, 2020 | 259 | 2020 |
| SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas N Rekhtman, J Montecalvo, JC Chang, D Alex, RN Ptashkin, N Ai, ... Journal of Thoracic Oncology 15 (2), 231-247, 2020 | 250 | 2020 |
| Lobectomy is associated with better outcomes than sublobar resection in spread through air spaces (STAS)-positive T1 lung adenocarcinoma: a propensity score–matched analysis T Eguchi, K Kameda, S Lu, MJ Bott, KS Tan, J Montecalvo, JC Chang, ... Journal of thoracic oncology 14 (1), 87-98, 2019 | 216 | 2019 |
| The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer AJ Schoenfeld, C Bandlamudi, JA Lavery, J Montecalvo, A Namakydoust, ... Clinical Cancer Research 26 (21), 5701-5708, 2020 | 205 | 2020 |
| Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers A Drilon, R Somwar, BP Mangatt, H Edgren, P Desmeules, A Ruusulehto, ... Cancer discovery 8 (6), 686-695, 2018 | 189 | 2018 |
| Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation A Quintanal-Villalonga, H Taniguchi, YA Zhan, MM Hasan, SS Chavan, ... Cancer discovery 11 (12), 3028-3047, 2021 | 117 | 2021 |
| Bronchiolar adenoma JC Chang, J Montecalvo, L Borsu, S Lu, BT Larsen, WD Wallace, ... The American journal of surgical pathology 42 (8), 1010-1026, 2018 | 115 | 2018 |
| Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS AR Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, Y Hu, ... Nature Communications 12 (1), 1-12, 2021 | 107 | 2021 |
| Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers M Offin, R Somwar, N Rekhtman, R Benayed, JC Chang, A Plodkowski, ... JCO precision oncology 2, 2018 | 105 | 2018 |
| Insights into pathogenesis of fatal COVID‐19 pneumonia from histopathology with immunohistochemical and viral RNA studies JL Sauter, MK Baine, KJ Butnor, DJ Buonocore, JC Chang, AA Jungbluth, ... Histopathology 77 (6), 915-925, 2020 | 101 | 2020 |
| Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intrapulmonary metastases: comparison with standard histopathologic … JC Chang, D Alex, M Bott, KS Tan, V Seshan, A Golden, JL Sauter, ... Clinical Cancer Research 25 (23), 7113-7125, 2019 | 86 | 2019 |
| Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements JC Chang, L Zhang, AE Drilon, P Chi, R Alaggio, L Borsu, R Benayed, ... Journal of Thoracic Oncology 14 (5), 825-834, 2019 | 80 | 2019 |
| Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices N Rekhtman, P Desmeules, AM Litvak, MC Pietanza, ML Santos-Zabala, ... Modern Pathology 32 (8), 1106-1122, 2019 | 77 | 2019 |
| Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes JC Chang, M Offin, CJ Falcon, DN Brown, B Loomis, F Meng, ... Clinical Cancer Research, 2021 | 68 | 2021 |
| Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset. CA Febres Aldana, JC Chang, R Ptashkin, Y Wang, E Gedvilaite, ... Clinical Cancer Research, 2022 | 55* | 2022 |
| POU2F3 in SCLC: Clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC MK Baine, CA Febres-Aldana, JC Chang, AA Jungbluth, S Sethi, ... Journal of Thoracic Oncology, 2022 | 52 | 2022 |
| MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance R Guo, M Offin, AR Brannon, J Chang, A Chow, L Delasos, J Girshman, ... Clinical Cancer Research 27 (3), 799-806, 2021 | 50 | 2021 |